Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Authors :: Léna Royston
Stavroula Masouridi-Levrat
Verena Gotta
Eva Royston
Caroline Pressacco-Brossier
Yasmine Abi Aad
David Tonoli
Abderrahim Karmime
Murielle Jayo
Christian Van Delden
Pierre Lescuyer
Marc Pfister
Yves Chalandon
Dionysios Neofytos
Source :: Antimicrobial agents and chemotherapy. 66(8)
Publication Year :: 2022
Abstract: With balanced safety-efficacy profile, letermovir anti-cytomegalovirus (CMV) prophylaxis is used in hematopoietic stem cell transplant recipients (HSCTR). We assessed feasibility and usefulness of letermovir therapeutic drug monitoring (TDM) in HSCTR. We performed a prospective observational study on letermovir-TDM including 40 consecutive adult CMV-seropositive allogeneic-HSCTR who received orally (PO) administered letermovir. Minimal blood concentrations of letermovir (C

Subjects :: Pharmacology
Adult
Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Graft vs Host Disease
Cyclosporins
Acetates
Antiviral Agents
Transplant Recipients
Infectious Diseases
Cytomegalovirus Infections
Quinazolines
Humans
Pharmacology (medical)
Drug Monitoring

Tools